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754Objectives:A single randomized trial established lobectomy as the standard of care for the surgical treatment of
early-stage non–small cell lung cancer. Recent advances in imaging/staging modalities and detection of smaller
tumors have once again rekindled interest in sublobar resection for early-stage disease. The objective of this
study was to compare lung cancer survival in patients with non–small cell lung cancer with a diameter of 30
mm or less with clinical stage 1 disease who underwent lobectomy or sublobar resection.
Methods:We identified 347 patients diagnosed with lung cancer who underwent lobectomy (n ¼ 294) or sub-
lobar resection (n ¼ 53) for non–small cell lung cancer manifesting as a solid nodule in the International Early
Lung Cancer Action Program from 1993 to 2011. Differences in the distribution of the presurgical covariates
between sublobar resection and lobectomy were assessed using unadjusted P values determined by logistic
regression analysis. Propensity scoring was performed using the same covariates. Differences in the distribution
of the same covariates between sublobar resection and lobectomy were assessed using adjusted P values deter-
mined by logistic regression analysis with adjustment for the propensity scores. Lung cancer–specific survival
was determined by the Kaplan–Meier method. Cox survival regression analysis was used to compare sublobar
resection with lobectomy, adjusted for the propensity scores, surgical, and pathology findings, when adjusted
and stratified by propensity quintiles.
Results: Among 347 patients, 10-year Kaplan–Meier for 53 patients treated by sublobar resection compared
with 294 patients treated by lobectomy was 85% (95% confidence interval, 80-91) versus 86% (confidence in-
terval, 75-96) (P¼ .86). Cox survival analysis showed no significant difference between sublobar resection and
lobectomy when adjusted for propensity scores or when using propensity quintiles (P¼ .62 and P¼ .79, respec-
tively). For those with cancers 20 mm or less in diameter, the 10-year rates were 88% (95% confidence interval,
82-93) versus 84% (95% confidence interval, 73-96) (P¼ .45), and Cox survival analysis showed no significant
difference between sublobar resection and lobectomy using either approach (P¼ .42 and P¼ .52, respectively).
Conclusions: Sublobar resection and lobectomy have equivalent survival for patients with clinical stage IA non–
small cell lung cancer in the context of computed tomography screening for lung cancer. (J Thorac Cardiovasc
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Abbreviations and Acronyms
CAC ¼ coronary artery calcification
CI ¼ confidence interval
CT ¼ computed tomography
HR ¼ hazard ratio
I-ELCAP¼ International Early Lung Cancer Action
Program
LCSG ¼ Lung Cancer Study Group
LR ¼ lobar resection
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
SLR ¼ sublobar resection
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SThe results of the randomized trial reported by the Lung
Cancer Study Group (LCSG) in 1995 established lobec-
tomy as the standard of surgical care for stage I non–small
cell lung cancer (NSCLC) in patients who are able to
tolerate the procedure.1 In that trial, conducted throughout
the 1980s, 276 patients with clinical stage I (cT1N0M0)
NSCLC detected on plain chest radiography were randomly
assigned to lobar resection (LR) or sublobar resection
(SLR) that included wedge resection or anatomic segmen-
tectomy. LR was associated with a lower rate of local recur-
rence and lung cancer–related deaths.
Important advances in clinical staging modalities and the
ability to detect smaller tumors by computed tomography
(CT) scans have led to a resurgence of interest in SLR for
early-stage lung cancer.2-12 Theoretic advantages of SLR
include preservation of lung parenchyma, pulmonary
function, and lower perioperative morbidity, thus enhancing
the possibilities of future resections for additional primary
lung cancers. The significant proportion of patients with
early-stage lung cancer who are not currently candidates
for LR because of impaired pulmonary function may be
safely and effectively treated by SLR provided that the sur-
vival outcome is equivalent to that ofLR. Several institutional
retrospective case series have suggested that recurrence and
survival may be similar after both types of resection.7-12 An
analysis from the large National Cancer Institute registry of
1165 patients with lung cancer with tumors 2 cm or less
showed that survival of 969 patients undergoing LR was
not significantly different from the 196 patients undergoing
SLR, even when accounting for covariates that might be
confounders (eg, age and comorbidities).13,14
The primary objective of the current work is to compare
the survival of patients with clinical stage I A NSCLC
(cT1N0M0) who were treated with LR or SLR in the Inter-
national Early Lung Cancer Action Program (I-ELCAP).
I-ELCAP is an international study that prospectively enrolls
all individuals from participating screening programs that
follow a common protocol that provides for data pool-The Journal of Thoracic and Caing.15,16 At the time of enrollment, participants are
asymptomatic for lung cancer, and pertinent baseline
demographic and clinical information are collected. CT
findings at baseline or annual repeat rounds of screening
are documented together with any subsequent diagnosis
of lung cancer, treatment, and follow-up. This large
resource offers a unique platform to examine the extent of
surgical resection for early-stage lung cancer diagnosed un-
der screening and provides the opportunity to further
address possible confounders of the decision to perform
LR or SLR.MATERIALS AND METHODS
The I-ELCAP database was queried for all patients diagnosed with a
first primary clinical stage I NSCLC (cT1N0M0) as a result of baseline
and subsequent annual CT screening from 1993 to 2011. The screenings
were performed according to a common protocol that specified the initial
CT test, the definition of positive results, and the recommended diagnostic
workup.15,16 The protocol required that all subjects be asymptomatic and
deemed by their physicians as suitable candidates for surgical resection
in the event that a diagnosis of lung cancer was made, but the enrollment
criteria as to age and smoking status was decided by each participating
institution. The extent of surgery, including the extent of mediastinal
lymph node sampling, was not mandated by the protocol but was
according to the standard of care at each institution. All screenees gave
informed consent for baseline and repeat screenings under institutional
review board–approved protocols at each of the participating institutions.
For the purposes of the current study, only patients whose lung cancer
manifested as a solid nodule on the CT scan were included. This classifica-
tion was performed by an experienced chest radiologist at the I-ELCAP
Coordinating Center. The data extracted for analysis included demographic
information, smoking history, and the self-reporting of the presence or
absence of 21 preexisting conditions. These 21 preexisting comorbidities
were categorized into 6 categories (cardiac diseases, vascular disease,
chronic obstructive pulmonary disease, diabetes, other non–lung cancers,
other diseases). The presence of each of these preexisting conditions was
coded as 1 (0 otherwise), and the sum was used as the cumulative comor-
bidity score.
Imaging information on the baseline CT scan included the presence and
extent of emphysema and coronary artery calcification (CAC). We previ-
ously reported that screening participants with marked emphysema were
found to be at increased risk of dying of emphysema and lung cancer,
and those with a CAC score of 4 to 12 had an increased risk of dying of cor-
onary artery disease.17-21
Once lung cancer was diagnosed, peripheral location of the tumor, clin-
ical staging, details of surgical treatment, results of pathologic examina-
tion, and survival status were documented. Although preoperative
pulmonary function test results were not initially documented in the I-EL-
CAP database, the presence and extent of emphysema on the baseline CT
scan were available on all patients and have been shown to be a surrogate
indicator of lung function.20 Tumor location was classified as peripheral if
it was within 2 cm of the costal pleura and otherwise as central. The clinical
stage of each patient was determined and entered into the database at the
time of initial diagnosis. Tumor diameter was the average of the length
and width of the tumor on the CT image that showed the largest cross-
section of the nodule before resection. The presence or absence of
lymph-node and distant metastases (N and M status) was assessed in the
most recent CT scan before diagnosis and from a positron emission tomog-
raphy (PET) scan, if performed. Nodal status was classified as N0 if the
widths of all mediastinal lymph nodes were less than 10 mm, no hilar
lymph nodes were identified, and the PET scan, if done, showed nordiovascular Surgery c Volume 147, Number 2 755
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general thoracic surgeons.
Each case was reviewed to determine the extent of resection and if
treated by SLR or LR, the former including by segmentectomy or wedge
resections. The number of nodal stations sampled or dissected at the time
of surgery also was documented. The surgical specimens were examined
at each institution according to the I-ELCAP pathology protocol.22 Histo-
logic slides of the tumors were sent to the Coordinating Center for review
and consensus diagnosis by a 5-member Pathology Review Panel following
the protocol.23,24 A member of the panel also reviewed all the slides to
identify pleural, lymphatic, and vascular invasion. Cell-type classification
for purposes of this report was adenocarcinoma, squamous cell carcinoma,
large-cell carcinoma, and other carcinoma (atypical carcinoid, sarcoma,
spindle cell/pleomorphic, non–small cell unspecified) according to the
World Health Organization criteria and subsequent reclassification of
adenocarcinoma, bronchioloalveolar subtype into adenocarcinoma in
situ.25,26
Recurrence and postoperative treatment were documented by each
participating institution. Recurrence was not further classified to local
regional or systemic. All patients were followed to death from lung cancer,
last contact, or April 30, 2013. Follow-up time ranged from 1 to 209
months, and median follow-up time was determined. All deaths from
lung cancer were recorded, including treatment-related mortality. At
each I-ELCAP participating institution, the time and cause of death were
ascertained in every case by direct family or referring physician contact
and recorded in the database.
Statistical Analysis
Differences in the distribution of demographic, clinical characteristics,
and comorbidity score for patients undergoing SLR or LR were evaluated
using logistic regression analysis based on the baseline characteristics,
findings on baseline CT scan, and presurgical CT scan to determine the un-
adjusted P values (Table 1). To ensure a balance of the covariates between
the 2 surgical treatments because there was nonrandom allocation to each
creating potential bias, propensity scoring was used as has been for other
similar analyses.15,16,23,24 The propensity score was calculated for each
patient using logistic regression analysis (1 assigned to SLR and 0 to
LR) based on each patient’s baseline characteristics, findings on
baseline, and presurgical CT scans (Table 1). This score represents the
probability of being assigned to 1 of the 2 types of surgery, SLR or LR, con-
ditional on all the covariates included in the propensity score determina-
tion. The regression analysis was then performed again to compare SLR
with LR for each covariate with the comparison being adjusted for the pro-
pensity score (adjusted P value, Table 1).
Lung cancer–specific survival was determined by the Kaplan–Meier
method. Ten-year Kaplan–Meier rates were determined for patients in
each of the 2 treatment groups, LR or SLR, for all cases, and those cases
with a diameter was 20 mm or less. Log-rank test was used to assess differ-
ences in the survival of the 2 treatment groups.
The multivariate Cox survival analysis was performed in 2 ways. First,
the SLR comparison with LRwas performed for all patients adjusted by the
propensity score and surgical and pathology findings (Table 2) not included
in the propensity score determination and then again, when stratified by the
propensity score quintiles. The same analysis is repeated for all those with
clinical stage IA disease for whom the presurgical tumor sizewas 20mm or
less. A secondary analysis was performed to compare SLRwedge resection
with LR and SLR segmentectomywith LR using Cox regression analysis as
detailed earlier. All analyses were performed using SAS version 9.2 soft-
ware (SAS Institute Inc, Cary, NC).RESULTS
NSCLC manifested as a solid nodule in 347 patients who
are the subject of this report. Lobectomy was performed in756 The Journal of Thoracic and Cardiovascular Surg294 patients, and SLR was performed in 53 patients (16 by
segmentectomy and 37 by wedge resection). The baseline
and presurgical covariates for the 2 groups are shown in
Table 1. The majority of patients were current or former
smokers of white ethnicity. Although there were fewer cur-
rent smokers in the SLR group than in the LR group (51%
vs 54%, P ¼ .27), the median pack-years of smoking was
slightly higher in the SLR group (50 vs 48, P ¼ .74), but
neither were significant. None of the self-reported comor-
bidities and the cumulative morbidity score were signifi-
cantly different, although SLR had more patients who
reported cardiac disease (11% vs 6%, P¼ .14) and chronic
obstructive pulmonary disease (26% vs 15%, P ¼ .05). On
the baseline CT scan, the frequencies of CAC (51% vs
52%, P ¼ .95), emphysema (47% vs 48%, P ¼ .95), and
marked emphysema (4% vs 4%, P ¼ .85) were essentially
identical for SLR and LR. The CAC score of 4 to 12 (26%
vs 18%, P ¼ .18), suggestive of coronary artery disease,
was more frequent in SLR than in LR, but these were not
significant. A total of 142 PET scans were performed; of
the 22 (37%) of the 53 patients treated by SLR and 120
(42%) of the 294 patients treated by LR, the 2 proportions
were not significantly different (P ¼ .92). After adjusting
for the propensity score, none of the covariates included
in creating the score were significant as shown by the
adjusted P values in Table 1.
Pathologic stage I disease was confirmed in 92%
(n ¼ 49) of the 53 patients treated by SLR and in 86%
(n ¼ 252) of the 294 patients treated by LR. Patients
treated by SLR had mediastinal lymph node resection
less frequently than those treated by LR (55% vs 79%,
P ¼ .0003) (Table 2). Among those who underwent medi-
astinal lymph node resection, the pathologic upstaging to
mediastinal disease (N2 and N3) occurred in 7% (2/29)
of patients with SLR and 4% (9/231) of patients with
LR. No significant differences were found between SLR
and LR for the pathology findings. Postsurgical treatment,
if any, was not significantly different (11% vs 13%,
P ¼ .75). There were no postsurgical deaths (within 1
month of surgery) in the patients with SLR and in 3 pa-
tients with LR. Lung-cancer specific death, including
any cause of death within 1 month of surgery, occurred
in 11% (6/53) and 11% (32/294) of patients with SLR
and LR, respectively, and death from all causes occurred
in 23% (12/53) and 24% (70/294) of patients, respec-
tively. The recurrence rate in the SLR group was higher,
but not significantly, than in the LR group (19% vs
12%, P ¼ .15). In the SLR group, all recurrences occurred
in those who had wedge resection.
The asymptote of the 10-year Kaplan–Meier survival
curve by SLR and LR was not significantly different,
86% (95% confidence interval [CI], 75-96) versus 85%
(95% CI, 80-91) (P ¼ .86) (Figure 1). Overall median sur-
vival time was 65 months, 61 months for SLR and 66ery c February 2014
TABLE 1. Presurgical characteristics of 348 patients with clinical stage I lung cancer less than 30 mm in diameter
Extent of surgery
Extent of resection P value
Lobectomy Sublobar resection Unadjusted Adjusted*
No. of cases 294 53
Baseline characteristics
Male gender 152 (52%) 29 (55%) .69 .91
Median age (IQR) 63 (59-68) 65 (59-72) .15 .95
40-49 y 9 (3%) 1 (2%)
50-59 y 65 (22%) 13 (25%)
60-69 y 158 (54%) 25 (47%)
70+ y 62 (21%) 14 (26%)
White ethnicity 253 (86%) 44 (83%) .56 .99
College education 103 (35%) 19 (36%) .91 .99
Smoking history
Never smoker 12 (4%) 4 (8%) Ref Ref
Former smoker 122 (41%) 22 (42%) .32 .87
Current smoker 160 (54%) 27 (51%) .27 .83
Median pack-years (IQR) 48 (35-68) 50 (38-70) .74 .96
Comorbidities
Cardiac 17 (6%) 6 (11%) .14 .84
Vascular disease 62 (21%) 12 (23%) .80 .93
COPD 45 (15%) 14 (26%) .05 .96
Diabetes 25 (9%) 4 (8%) .82 1.00
Other cancer 40 (14%) 7 (13%) .94 .95
Other diseases 58 (20%) 10 (19%) .88 .88
Median comorbidity score (IQR) 1 (0-1) 1 (0-2) .49 y
Findings on baseline CT
Emphysema
Any 140 (48%) 25 (47%) .95 y
Marked 13 (4%) 2 (4%) .83 .98
Coronary calcification
Any 154 (52%) 27 (51%) .85 y
CAC score 4-12 54 (18%) 14 (26%) .18 .88
Findings on CT before surgery
Peripheral location on CT 205 (69%) 38 (74%) .77 .93
Nodule diameter on CT
20 mm 256 (87%) 50 (94%) .14 .89
21-30 mm 38 (13%) 3 (6%)
CAC, Coronary artery calcification; COPD, chronic obstructive pulmonary disease; CT, computed tomography; IQR, interquartile range. *Adjusted for propensity score. yNot
included in propensity score model.
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the propensity score and postsurgical and pathology find-
ings, resulted in a hazard ratio (HR) of 1.3 (95% CI, 0.5-
3.3; P ¼ .62; Table 3). When stratified by the propensity
score quintiles, the Cox survival analysis resulted in an
HR of 1.1 (95% CI, 0.4-2.9; P ¼ .79). In both of these
Cox survival analyses, only T1 increased survival time
significantly compared with T2-T4 (P ¼ .003 and
P ¼ .003, respectively).
By comparing only 306 patients whose tumor diameter
before surgery was 20 mm or less, 256 were treated by
LR and 50 were treated by SLR. Recurrence in the
SLR group was higher, but not significantly, than in the
LR group (20% vs 10%, P ¼ .21). Mediastinal lymph
node resection was performed less frequently in theThe Journal of Thoracic and CaSLR group than in the LR group (55% vs 80%,
P ¼ .0002). The 10-year asymptote of the Kaplan-Meier
survival for patients treated by SLR and LR was 88%
(95% CI, 82-93) versus 84% (95% CI, 73-96), respec-
tively, but was not significantly different (P ¼ .45)
(Figure 2). Cox survival analysis, after adjustment for
the propensity score and postsurgical and pathology find-
ings, did not demonstrate a significant difference
between SLR and LR (HR, 1.5; 95% CI, 0.6-4.2;
P ¼ .42) (Table 3). When stratified by propensity score
quintiles, there was no significant difference (HR, 1.4;
95% CI, 0.5-3.8; P ¼ .52). In both of these Cox survival
analyses, only T1 increased survival time significantly
compared with T2-T4 (P ¼ .004 and P ¼ .005,
respectively).rdiovascular Surgery c Volume 147, Number 2 757
TABLE 2. Mediastinal lymph node resections and pathology findings of 348 patients with clinical stage I lung cancer less than 30 mm in diameter
Extent of surgery
Extent of resection P value
Lobectomy Sublobar resection Unadjusted Adjusted*
No. of cases 294 53
Mediastinal lymph node resection
Any resected 231 (79%) 29 (55%) .0003 y
Any metastases 9 (4%) 2 (7%) .79 y
Pathologic findings
Carcinoma cell-type
Adenocarcinoma 191 (65%) 36z (68%) Ref y
Squamous cell 72 (24%) 11 (21%) .68
Large cell 25 (9%) 4 (8%)
Other 6 (2%) 2 (4%)
Pathology tumor diameter
20 mm 239 (81%) 49 (92%) .07 y
>20 mm 55 (19%) 4 (8%)
Pathologic invasion
Pleura invasion 80 (27%) 10 (19%) .21 y
Angiolymphatic invasion 53 (18%) 6 (11%) .24 y
pT status
T1: 30 mm without pleura invasion 197 (67%) 40 (75%) Ref y
T2: 30 mm and pleural invasion 75 (26%) 10 (19%) .23
T2: 30 mm without pleural invasion 5 (2%) 1 (2%)
T3: additional Ca in same lobe 16x (5%) 0 (0%)
T4: additional Ca in ipsilateral lobe 1 (0%) 2 (4%)
pN status
N0 267 (91%) 51 (96%) Ref y
N1 18 (6%) 0 (0%) .21
N2 8 (3%) 2 (4%)
N3 1 (0%) 0 (0%)
Ca, Cancer. *Adjusted for propensity score. yThese variables were not included in the propensity score model. zOne adenocarcinoma in situ, mucinous subtype. xFivewith pleural
invasion.
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who underwent anatomic segmentectomy, but recurrence
occurred in those who underwent wedge resection (0% vs
27%, P ¼ .95). The baseline or presurgical covariates
were not significantly different between those who under-
went segmentectomy compared with wedge resection.
The asymptote of the Kaplan–Meier survival curve for
SLR segmentectomy and SLR wedge was 100% and
80% (66%-95%), respectively (P ¼ .12). Cox survival
analysis comparing SLR segmentectomy with LR, adjusted
for the propensity scores and postsurgical and pathology
findings, was not significantly different (P ¼ .99). SLR
wedge compared with LR, whether adjusted for the propen-
sity scores (P ¼ .19) or stratified by propensity quintiles
(P ¼ .17), was not significantly different (Table 3).
There was no significant difference in lung cancer sur-
vival between patients with lung cancers 30 mm or less in
diameter when treated by LR or SLR, when considering po-
tential confounders and different analyses.
DISCUSSION
The debate about the role of SLR in the treatment of early-
stage lung cancer has occupied thoracic surgeons for758 The Journal of Thoracic and Cardiovascular Surgdecades.2-12 The debate was partly resolved by the
publication of the results of the randomized trial conducted
by the LCSG showing that in comparison with LR, SLR
was associated with a 3-fold increase in local recurrence
and a 50% increase in cancer-related deaths.1 LR, whenever
possible, has since become the preferred procedure.
Renewed interest in SLR has been fueled by several fac-
tors; foremost among them is that the LCSG trial was con-
ducted in the 1980s on the basis of lung cancer detection
by plain chest radiography and before the routine use of
CT and more recently PET as standard staging modalities
for lung cancer. Many of these patients possibly had unde-
tected metastatic disease. There has also been a notable in-
crease in the detection of smaller tumors than those
included in the LCSG trial using recent generation CT
scanners. With the reports of increased curability of lung
cancer27 and the publication of the National Lung
Screening Trial showing that CT screening for lung cancer
reduced the relative lung cancer mortality when compared
with chest radiographic screening,28 the number of
patients presenting with small tumors will continue to in-
crease. Because more of these patients are cured of their
first primary lung cancer, they are also likely to developery c February 2014
FIGURE 1. Kaplan–Meier survival curves for 337 patients with clinical stage IA lung cancer manifesting as a solid nodule (nodule diameter of30 mm),
separately for those who underwent lobectomy (n ¼ 294) and SLR (n ¼ 53). CI, Confidence interval.
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become increasingly important. There also has been a
steady increase in the proportion of elderly patients pre-
senting with incidentally detected, potentially curable
early-stage disease, and in these patients SLR may be
associated with lower morbidity and equivalent survival
to lobectomy.29
The principal finding of this report is that SLR had equiv-
alent survival outcome as LR in patients with screen-
detected clinical stage IA lung cancers manifesting as aTABLE 3. Cox regression analysis for sublobar resection compared
with lobectomy with the hazard ratio, adjusted for propensity scores




Entire cohort (N ¼ 347)
SLR vs lobectomy
Adjusted by propensity score 1.3 (0.5-3.3) .62
Stratified by propensity score quintiles 1.1 (0.4-2.9) .79
Cohort 2 cm (N ¼ 306)
SLR vs lobectomy
Adjusted by propensity score 1.5 (0.6-4.2) .42
Stratified by propensity score quintiles 1.4 (0.5-3.8) .52
Secondary analysis (N ¼ 331)
Wedge resection vs lobectomy
Adjusted by propensity score 1.9 (0.7-5.0) .19
Stratified by propensity score quintiles 2.0 (0.7-5.3) .17
CI, Confidence interval; HR, hazard ratio; SLR, sublobar resection.
The Journal of Thoracic and Casolid nodule, when controlling for potential confounders.
The tightly controlled prospective acquisition of data ele-
ments, including comorbidities, presence of emphysema,
and CAC on the baseline CT scan and the use of the propen-
sity scoring to create a balance of the covariates between the
2 surgical treatments, supports the validity of these findings.
Another important finding is the remarkably low surgical
mortality (0.9%) in this screen-detected cohort treated by
general thoracic surgeons at centers with specialized
screening programs. We believe that the low operative mor-
tality in this report and that reported in the American Col-
lege of Surgeons Oncology Group Z030 trial30 are more
representative of the current state of the art rather than the
5% mortality frequently cited in the literature.
Our results are similar to those previously reported in a
study using the National Cancer Institute–sponsored regis-
try that included 1165 patients, of whom 969 were treated
by LR and 196 were treated by SLR.13 In that study, survival
of patients with stage IA tumors 20 mm or less was similar
for both treatment modalities. Notwithstanding our data and
those of others supporting SLR, there are a number of re-
ports that assert that SLR is associated with higher local
recurrence rates and inferior disease-free survival and
should be reserved for patients at high risk for LR.31,32 A
recent meta-analysis comparing LR with SLR performed
in the 1990s and early 2000 showed a statistically insignif-
icant survival advantage of LR.33 However, there was
considerable heterogeneity among studies in both patient
selection criteria and tumor characteristics. Most studiesrdiovascular Surgery c Volume 147, Number 2 759
FIGURE 2. Kaplan–Meier survival curves for 306 patients with clinical stage IA lung cancer manifesting as a solid nodule (nodule diameter of20 mm),
separately for those who underwent lobectomy (n ¼ 256) and SLR (n ¼ 50). CI, Confidence interval.
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generally not regarded by most thoracic surgeons as onco-
logically equivalent operations. As video-assisted thoraco-
scopic surgery becomes the state-of-the-art practice for
surgery in the context of screening, these issues will
continue to be revisited.34
The assignment of patients in this study to SLR or LR
clearly was not randomized; therefore, the possibility that
patients with limited pulmonary reserve were not selected
for LR cannot be excluded. However, the use of propensity
scoring provides a methodology for correcting for this po-
tential recruitment bias because it mimics randomization
by creating comparable samples of individuals who under-
went SLR and LR on the basis of the covariates. The pres-
ence of emphysema on the baseline CT scan at the time of
enrollment is a reasonable surrogate of pulmonary function
and has been shown to be a significant predictor of death
from chronic obstructive pulmonary disease and lung can-
cer.17-21 In addition, the proportion of patients with
marked emphysema and CAC score were not significantly
different between the 2 treatment groups. Finally, because
only a small proportion of patients in the SLR group had
tumors larger than 2 cm, our conclusions cannot be
extended with a high degree of confidence to the
treatment of patients with T1b disease.
An interesting observation is that even in the hands of
qualified thoracic surgeons, 21% and 43% of patients
treated by LR and SLR, respectively, did not have anymedi-
astinal nodal sampling. This imbalance in surgical medias-
tinal staging may have adversely affected the outcome after760 The Journal of Thoracic and Cardiovascular SurgSLR because the LR group would have been more thor-
oughly staged. However, despite this imbalance, there was
no difference in survival between the 2 groups. Clearly,
regardless of the extent of parenchymal resection, appro-
priate staging of the mediastinum should be performed
whenever possible because it has important therapeutic
and prognostic implications. Another important surgical
question is the frequency of local and loco-regional recur-
rence between the 2 treatment groups and between the 2
forms of SLR. Several studies, including the randomized
trial by the LCSG, showed that SLR was associated with
a significantly higher incidence of local recurrence and a
50% increase in cancer-related deaths.1,4 Others have
suggested that in appropriately selected patients, local
failure rates were similar regardless of the extent of
parenchymal resection.7,8 There are important differences
between these studies in patient selection criteria and the
type of SLR performed, particularly because wedge
resections are reportedly associated with a significantly
higher local recurrence rate compared with anatomic
segmentectomy.35 We found no significant difference be-
tween LR and wedge SLR, but segmentectomy had a lower
recurrence rate than wedge SLR, although the small sample
size of the SLR group somewhat limits this result. Planned
future studies and the ongoing randomized trials should
provide the answers to these critical questions.
CONCLUSIONS
To our knowledge, this is the first report on the merits of
SLR in the context of screening, and it focuses only on lungery c February 2014
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Scancers manifesting as solid nodules. The finding that LR
and SLR are associated with similar lung cancer–specific
survival in screen-detected cancers will add to the treatment
options for patients with early-stage lung cancer as wider
implementation of screening develops. The important
debate about the role of SLR in the treatment of early-
stage lung cancer will ultimately be resolved by the ongoing
adequately powered randomized trials conducted in North
America by the Alliance of Clinical trials in Oncology
(Cancer and Leukemia Group B 140503) and in Japan by
the Japanese Clinical Oncology Group.
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Dr Joseph Friedberg (Philadelphia, Pa). The role of SLRs has
been the focus of intense scrutiny by thoracic surgeons for de-
cades, and the exact role has yet to be rigorously defined. We
are still forced to fall back on the LCSG analysis from 1995 as
the final word until the upcoming randomized trials from the Can-
cer and Leukemia Group B and the Japanese Clinical Oncology
Group are completed. Your study provides more compelling
evidence, however, that there is clearly a role for SLR in some
of our patients.
My first question relates to the study population. As I read
the article, I was struck at how astoundingly well matched
the 2 groups were in this study, right down to the percentage
with college educations. I believe this is a particular strength
of this study in that it allows for an accurate assessment of out-
comes attributable to the surgical procedure. A potential weak-
ness of this study, however, arises from this same degree of
uniformity. Specifically, this study is based on a subgroup of
a subgroup—a group of patients who qualified for and enrolled
in a lung cancer screening trial and then developed solid nod-
ules while in that trial. Do you offer any cautions or see
any reasons why your results would not apply to the more gen-
eral population of patients with lung cancer we see in our
practices?
Dr Altorki. I don’t believe this study is a practice-changing
study. However, it is a study that calls for more equipoise in
terms of our approach to the treatment of lung cancer using
limited resections. We have applied these operations in patients
who would be candidates for both lobectomy and SLR. Patients
who are poor candidates for lobectomy should be treated by
SLR.
Dr Friedberg. My second question centers on another un-
usual situation for the general population of patients with lung
cancer. All of these patients had their surgery performed by gen-
eral thoracic surgeons, not just general thoracic surgeons, but
highly qualified general thoracic surgeons. Within this context,
I was surprised that 70% of the SLRs were performed as
wedges, not anatomic segmentectomies. I was also surprised
that more than 40% of the patients undergoing SLR and approx-
imately one quarter of the patients undergoing lobectomy did
not have even 1 mediastinal lymph node biopsied. One
would expect, on the basis of the LCSG analysis and common
sense, that some of these patients, especially those undergoing
SLR, were understaged or undertreated, yet the results
are as good as anything in the literature. How do you reconcile
that?ery c February 2014
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SDr Altorki. Let me take the second part first. I do agree with
you that the assessment of the mediastinal nodes was disap-
pointing. However, it exceeds what is in the published literature.
We need to further educate about the therapeutic and prognostic
impact of mediastinal nodal staging, particularly in patients in
whom an SLR is performed.My guess is that most of these patients
underwent video-assisted thoracic surgery, and, as you know,
mediastinal nodal assessment by video-assisted thoracic surgery
may not be as straightforward as it is by the open procedure, so
that’s probably why they were skipped.
To go back to the wedge resection, many may have thought
going into this that a 1-cm or 1.2-cm tumor may be effectively
treated by wedge resection, and that is the job we have to address
in the ongoing randomized trials to try and clarify if there is indeed
a role for wedge resection.
Dr Friedberg. I am curious about the decision to omit patients
with ground-glass opacities from the study. I suspect many of us,
given the controversy surrounding SLR, are more likely to be
aggressive with using SLRs for a slowly progressing ground-glass
opacity than a solid nodule. Do you know how many patients were
excluded from the study because their nodules weren’t solid and
do you have any thoughts on the applicability of SLRs for these
patients?
Dr Altorki. We had this discussion, and I voted strongly to
exclude them. I do believe that they are a group of patients who
exhibit a different biological behavior than those with solid nod-
ules, and we wanted to focus on a specific group of patients. But
I agree with you that this is a group that needs to be studied and
we hope to report on.
Dr Friedberg. They are the ones who are more likely to
develop something down the road requiring additional surgery. It
seems to me they would be the best candidates for this.
Dr Altorki. I think they are good candidates for SLR, yes, but I
do think they have to be studied separately.
Dr Scott Swanson (Boston, Mass). I like this study, Nasser. I
was struck by the 5% of second tumors in the lobectomy specimen.
Presumably it is the same in the wedge, but the local recurrence
rates weren’t different. Do you have any data about little nodules
that were being followed in that wedge group and what happened
or why that is?
Dr Altorki. That number is consistent with the published liter-
ature from Japan specifically and from our institution outside of
the I-ELCAP. These are usually not detected clinically on the
CT scans. We do have some patients in the Cancer and Leukemia
Group B trial in whom a wedge resection was performed, and even
in thewedge, there are additional nodules. The bottom line is that it
did not affect lung cancer–specific survival. But I’m concerned
about them, as you are.
Dr L. Penfield Faber (Chicago, Ill). Dr Altorki, I compliment
you on an excellent presentation. I would also like to thank my
good friends, Drs Thurer, Kohman, and Harvey Pass, for substan-
tiating the surgical concept of surgical resection for primary lung
cancer that Dr Jensik and I reported on 34 years ago, both qualified
general thoracic surgeons. We described 168 patients with a 53%
5-year survival. We resected larger tumors, greater than 3 cm, and
our lymph node staging was inadequate, and I think that accounts
for our low survival compared with what we see today. With theThe Journal of Thoracic and Caguidelines reported today, I believe segmental resection for pri-
mary lung cancer is a good operation.
Dr Altorki. I have to acknowledge the pioneering contribution
of Dr Faber and, as a displaced Chicagoan, of Dr Jensik as well. So
I thank you for your efforts.
Dr Jose Rodriguez (Dayton, Ohio). I noticed that in your 51 or
52 SLRs, there were maybe 18 that were segmentectomies. It was
not exactly described whether theywere anatomic or nonanatomic.
Do you think that it is a low number of segmentectomies to
compare with approximately 200 lobectomies? Do you think
that it is a low-power study to say that a segmentectomy might
be better?
I noticed that 4% to 6% of your SLRs were upstaged to stage
II or III because of N1 or N2 unexpected disease. What did you
do with those patients? Now you need to give adjuvant treatment,
and, in my opinion, they received maybe a suboptimal resection
for a stage II or III. I would be concerned that we are advising
surgeons to do an SLR when we are going to have maybe 5%
to 7% or 10% of patients who will have a suboptimal resection
due to unexpected stage II and III. I would like you to comment
on that.
Dr Altorki.We are not advising the surgeon to do anything.We
are just advising the surgeon to develop some equipoise. We
advise the surgeon that the data from the LCSG are no longer rele-
vant and that you should approach this whole matter with a new
frame of mind. We need to do a study that compares one with
the other.
Dr Daniel Miller (Atlanta, Ga). Did you go back and look at all
and see if there was a difference in the pathologic upstaging in re-
gard to a nodule that was found on the incident scan versus the
prevalent scan? Many times when we have found these original
nodules, they are a bit more biologically active, they might already
have nodal involvement and so forth. It would be an interesting
question. As we look at the follow-up scans, those might be better
survival and so forth and be something to look at because you have
a larger number of patients.
Dr Altorki. You are saying segregate the cancers on the base-
line from the cancers on the annual repeat?
Dr Miller. Exactly, yes.
Dr Altorki. That information has been published by I-ELCAP
before. Conceptually, though, we do think those that occur on the
annual repeat are more likely to be the more aggressive ones than
those detected on the baseline scans. I agree with you.
Dr Caio Sterse Da Mata (Sao Paulo, Brazil). What was the
criteria you used to perform a wedge versus a segmentectomy?
Dr Altorki. These patients were involved in the local screening
program, and the management was left to the local tumor commit-
tees of the local hospitals. We did not mandate any type of resec-
tion or how the resection should be done.
Dr Da Mata. There was no inclusion or exclusion criteria for
this?
Dr Altorki. No. The local surgeon, who was usually a board-
certified or equivalent certified thoracic surgeon, made the deci-
sion about that.
Dr Frank Detterbeck (New Haven, Conn). Dan Miller is al-
ways a step ahead of me and asked more or less the question I
wanted to ask.rdiovascular Surgery c Volume 147, Number 2 763
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SI have 2 follow-up points. You can look at your data to find out
how many of these were baseline versus follow-up scans and do
that analysis, and I would stimulate you to perhaps ask the ques-
tion: In your practice, because you are in an area where there is
a fair amount of screening performed, but there is also a fair
amount of incidental scanning going on, can you look at whether
incidental scanning gives us similar results to screening? That
would have a lot of impact in the generalizability of the results
that you have just reported.
Dr Altorki. The crux of the question is that these were patients
in a screening trial, and therefore they were a special cohort. I
accept that, and we don’t say that in our summary statement.764 The Journal of Thoracic and Cardiovascular SurgDoes that translate into what you find in somebody who comes
to your office with a CT scan in hand? I think to answer that ques-
tion we have an ongoing randomized trial.
Dr Joseph Shrager (Stanford, Calif). I want to go back to the
issue of the tumor formerly known as bronchioloalveolar carci-
noma. You said solid nodules, but does that mean part-solid
nodules? You don’t have any nodules in there that are half
ground-glass or anything like that?
Dr Altorki. No. We excluded all part-solid and nonsolid nod-
ules from this analysis.
Dr Shrager. Okay. I think that’s a really important point.
Dr Altorki. I agree with you, yes.ery c February 2014
